恒瑞医药心肌肌球蛋白抑制剂HRS-1893达成海外授权，里程碑付款最高可达10.13亿美元

Core Viewpoint - HengRui Medicine has entered into an exclusive licensing agreement with Braveheart Bio for the development and commercialization of its proprietary Myosin small molecule inhibitor HRS-1893 outside of Greater China [1] Group 1: Licensing Agreement Details - HengRui Medicine grants Braveheart Bio exclusive rights to develop, manufacture, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1] - Braveheart Bio will pay a total of $75 million, which includes a $65 million upfront payment ($32.5 million in cash and $32.5 million in Braveheart Bio equity) and a $10 million milestone payment upon completion of technology transfer [1] Group 2: Potential Financial Gains - HengRui Medicine is eligible to receive up to $1.013 billion in milestone payments related to clinical development and sales, along with corresponding sales royalties [1]